Insider Transactions in Q3 2021 at Monopar Therapeutics (MNPR)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2021
|
Michael J Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+0.35%
|
-
|
|
Sep 30
2021
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,155
-4.14%
|
$4,620
$4.87 P/Share
|
|
Sep 30
2021
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,941
+12.37%
|
-
|
|
Sep 30
2021
|
Arthur J Klausner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+8.08%
|
-
|
|
Sep 30
2021
|
Raymond Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+14.19%
|
-
|
|
Sep 30
2021
|
Christopher M Starr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
751
+17.49%
|
-
|
|
Sep 30
2021
|
Kim R Tsuchimoto Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
423
-10.87%
|
$1,692
$4.87 P/Share
|
|
Sep 30
2021
|
Kim R Tsuchimoto Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,221
+23.88%
|
-
|
|
Sep 30
2021
|
Andrew Paul Mazar Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
471
-2.46%
|
$1,884
$4.87 P/Share
|
|
Sep 30
2021
|
Andrew Paul Mazar Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,606
+7.74%
|
-
|